Le Lézard
Classified in: Health, Science and technology
Subject: AWD

Elucid Bioimaging Announces Notice of Award


WENHAM, Mass., May 17, 2019 /PRNewswire-PRWeb/ -- Elucid Bioimaging, Inc. today announced that that it has been awarded a highly-competitive Phase IIB Bridge Award from the National Heart, Lung, and Blood Institute of the NIH for its atherosclerosis evaluation software vascuCAP®. According to the funding opportunity announcement, the purpose of the SBIR IIB is to "facilitate and accelerate the capital-intensive steps that are required to transition to the commercialization stage by promoting partnerships between awardees and third-party investors and/or strategic partners."

The competitive review criteria for considering grant applications under this program include scientific merit, clinical utility, and strength of the commercialization plan. Quoting from the NIH's study section's summary statement, "As assessed in peer review, the main strengths of the application are the clinical value of being able to image unstable plaque, the potential of the product to reduce costs and duration of clinical trials of drugs targeting atherosclerosis, the value in the planned retrospective study as it would promote some level of acceptance and can be done on a compressed timeline, a high degree of innovation in the utilization of artificial intelligence and deep learning in the software, a well-qualified project team, a well-conceived commercialization plan, an appropriate regulatory strategy, and a strong environment."

"Despite advances in the care and management of patients with cardiovascular disease, it remains the largest cause of death and disability worldwide. We are pleased that vascuCAP®'s innovative incorporation of deep biological insights together with progressive machine intelligence is increasingly recognized as ground breaking," said Andrew Buckler, President of Elucid. "This grant award broadens our base of validated measurements and phenotype classification functionality while simultaneously providing substantial primary data for documenting vascuCAP®'s clinical utility and cost effectiveness in improving patient outcomes."

About Elucid Bioimaging Inc.
Elucid is a biomedical engineering company with a unique portfolio of expertise at the crossroads of quantitative medical imaging, clinical trials, surrogate endpoints and big data to enable its Computer Aided Phenotyping® or CAP® diagnostics platform. Elucid's first commercial product, vascuCAP® provides multi-dimensional visualization and measurements to aid clinicians in their analysis of arterial anatomy and tissue characteristics. With vascuCAP®, tissue characteristics implicated in high risk atherosclerotic plaque may be quantitatively measured from CT Angiography (CTA) in coronary, carotid, femoral and other arteries with high correlation with histopathology. vascuCAP® is available in the US under FDA 510(k) K183012, under a CE mark in Europe, and in a Research Edition configuration for clinical research studies. To learn more, visit http://www.elucidbio.com or contact Samantha St. Pierre at samantha.stpierre@elucidbio.com.

 

SOURCE Elucid Bioimaging, Inc.


These press releases may also interest you

at 03:00
One of the most popular names from "The Matrix" and "John Wick" series also utilizes his talents in the world of informational television. "Behind the Scenes" with Laurence Fishburne is a popular series that seeks to bring attention to some of the...

at 03:00
Board Certified plastic surgeon, Brian S. Glatt, MD, FACS has been reviewed and approved by NJ Top Docs for 2019. Dr. Glatt, a Fellow of the American College of Surgeons, is licensed to practice plastic and reconstructive surgery in New Jersey and...

19 jui 2019
The highly anticipated Microsoft Inspire 2019 was held on July 14-18, 2019.  At the conference, 21Vianet Blue Cloud (hereafter "21V Blue Cloud") announced their new solution partners and introduced the AggreSmart solution platform (public preview) to...

19 jui 2019
HyperBlock Inc. ("HyperBlock" or the "Company") confirmed today that the first batch of a US $1.1M shipment of Bitmain's new 7nm Bitcoin mining servers has arrived on North American shores. HyperBlock expects to fully deploy the new servers this...

19 jui 2019
This Saturday 20 July, The Aldrin Family Foundation will host a free family celebration with The People's Moon transforming New York's Times Square into Tranquillity base celebrating the 50th Anniversary of when humans first walked on the Moon taking...

19 jui 2019
Laboratory Medicine Consultants, Ltd. ("LMC") has been informed by Retrieval Masters Creditors Bureau d/b/a American Medical Collection Agency ("AMCA") of a data security incident involving the AMCA payment website. AMCA is an independent collection...



News published on 17 may 2019 at 20:00 and distributed by: